Home>Topics>Funds>Morgan Stanley Ins Muni Secs

Morgan Stanley Ins Muni Secs XIMSX

  1. All
  2. Commentary
  3. Headlines
    1. BRIEF-Cegedim says definitive deal executed for its CRM and strategic data division with IMS Health

      Headlines

      Mon, 20 Oct 2014

      * Says definitive deal has been executed for its CRM and strategic data division with IMS Health Inc. for cash price of 385 million euros

    2. Belviq Sales Dip: What To Watch For Ahead

      Headlines

      Fri, 17 Oct 2014

      of seasonality with ups and downs as the Fall weeks progress. This week sales declined 1.8% according to industry tracker IMS Health. Sales for the week ending October 10th were just under 12,200, representing a slight dip from the previous week. There

    3. Is It Time To Consider OncoMed Pharmaceuticals Again?

      Headlines

      Tue, 14 Oct 2014

      increase to between 20 million and 26 million. A report from IMS Health shows that despite moderating in recent years, global spending on oncology drugs reached $91 billion in 2013. IMS Health further notes in its report that the share of targeted

    4. With Harvoni Approved, Here's What's Next For Gilead Sciences

      Headlines

      Tue, 14 Oct 2014

      the company's future prospects. Scrip trends Sovaldi sales have taken a hit over the past couple of months. According to IMS , total weekly prescriptions have fallen from 6,804 in late August , to 5,393 for the week ending October 3. Should the count

    5. IMS to report on October 24

      Headlines

      Fri, 10 Oct 2014

      IMS Health Holdings ( IMS -0.1% ) will report Q3 results on October 24 before the open. The conference call will begin at 9:00 am ET. Consensus view is EPS of $0.34 on revenues of $668M. Post your comment!

    6. Cegedim Will Be Rerated Following The IMS Transaction

      Headlines

      Thu, 9 Oct 2014

      By Early Retiree : (Editor's Note: Investors should be mindful of the risks of transacting in securities with limited liquidity, such as CGMJF. Cegedim's stock listing in Paris, CGM.PA, offers stronger liquidity.) Introduction Cegedim SA (OTC: CGMJF ) is a French IT company that produces and ...

    7. Belviq Sales Flat - Model Your Expectations

      Headlines

      Fri, 3 Oct 2014

      Pharmaceuticals' (NASDAQ: ARNA ) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE: IMS ). Script sales came in at about 11,800, and were down 0.5%. The numbers reported were as of September 26th

    8. Akorn buys rights to bronchodilator

      Headlines

      Wed, 1 Oct 2014

      20M to Akorn's top line and $0.07 - 0.08 to EPS in 2015 excluding the impact of acquisition-related amortization. Per IMS Health, the U.S. market for the branded and generic versions of Xopenex is ~$280M. Post your comment!

    9. IG Labs acquires products from Valeant

      Headlines

      Wed, 1 Oct 2014

      injectable drug products from affiliates of Valeant Pharmaceuticals ( VRX -1.4% ). All have been approved via ANDAs or NDAs. Per IMS Health, the U.S. market for the drugs is ~$38M. Specific financial terms of the transaction are undisclosed. Post your

    10. Belviq Sales Benefit From Advertising - Up 2.8%

      Headlines

      Fri, 26 Sep 2014

      Pharmaceuticals (NASDAQ: ARNA ) saw a nice week over week gain on the heels of a more robust advertising campaign. According to IMS Health, script sales this week were about 11,900 which represents a gain of 2.8% over last weeks numbers. While a 2.8

    « Prev12345Next »
    Content Partners